ReviewInternational ophthalmology2011
Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.
Review in International ophthalmology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Anti-TNF Drugs for Chronic Uveitis in Adults-A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Frontiers in medicine · 2019Pooled it
- Immunogenicity of adalimumab in patients with noninfectious uveitis based on therapeutic drug monitoring.Journal of translational medicine · 2025Article
- A Human Factors Validation of a Smart Autoinjector Accessory Designed to Improve Self-Injection Outcomes and User Confidence.Medical devices (Auckland, N.Z.) · 2025Article
- Evaluation of Methods Employed in Establishing Preclinical Similarity of Adalimumab Biosimilars.Advances in pharmacological and pharmaceutical sciences · 2025Review
- Therapeutic potential ofHeliyon · 2024Article
- The Efficacy of Adalimumab in Children with Chronic Non-infectious Posterior Uveitis and Panuveitis: A Retrospective Cohort Study.Ophthalmology and therapy · 2024Article
- Cause analysis of conversion to biologics in spondyloarthritis patients with poor response to conventional treatment.Clinical rheumatology · 2023Article
- Freeze-dried amniotic membrane graft with a spongy layer in bilateral peripheral ulcerative keratitis: a case report.BMC ophthalmology · 2023Article
- Article
- Increased Risk of Acute Coronary Syndrome in Ankylosing Spondylitis Patients With Uveitis: A Population-Based Cohort Study.Frontiers in immunology · 2022Article
- New pharmacotherapy options for noninfectious posterior uveitis.International ophthalmology · 2021Review
- Identification of potential TNF-α inhibitors: from in silico to in vitro studies.Scientific reports · 2020Article
- Effects of ROCK Inhibitors on Apoptosis of Corneal Endothelial Cells in CMV-Positive Posner-Schlossman Syndrome Patients.Investigative ophthalmology & visual science · 2020Article
- Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study.Mediators of inflammation · 2019Article
- Outcome of Juvenile Idiopathic Arthritis Associated Uveitis in Two Disease Subtypes.Archives of rheumatology · 2017Article
- Profile of adalimumab and its potential in the treatment of uveitis.Drug design, development and therapy · 2016Review
- Anti-TNFα agents and methotrexate in spondyloarthritis related uveitis in a Chinese population.Clinical rheumatology · 2015Article
- Increased CD1c+ mDC1 with mature phenotype regulated by TNFα-p38 MAPK in autoimmune ocular inflammatory disease.Clinical immunology (Orlando, Fla.) · 2015Article
- Success with single-agent immunosuppression for multifocal choroidopathies.American journal of ophthalmology · 2014Article
- Infliximab for peripheral ulcerative keratitis treatment.Medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor necrosis factor alpha (TNF-α) is a key soluble mediator involved in the inflammatory cascade of many disorders including uveitis. Among the anti-TNF-α agents, one of the most used in immune-mediated diseases, such as inflammatory arthropathies, is adalimumab (Humira™, Abbott Pharmaceutical Inc.), a fully humanized antibody. The purpose of this review is to analyze the main pharmacological and clinical aspects of adalimumab and its efficacy both in systemic and ocular inflammatory disorders. Adalimumab was effective in treating several autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. In recent years, adalimumab has been used successfully in refractory cases of intraocular inflammation. Moreover, this biological agent showed good safety and efficacy profiles in ocular use including childhood uveitis. Switching from other anti-TNF-α agents to adalimumab may offer several advantages, such as easier administration, better patient compliance, and lower rate of adverse events. Adalimumab is a promising drug for the therapy of uveitis, although further studies are needed on its application in uveitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.